Group 1 - The company's revenue for the year ending December 31, 2024, is projected to be RMB 71.9 million, representing a year-on-year increase of 7.9% due to improved market penetration of its product, Uterilone Injection [1] - The company's loss has decreased from RMB 189.6 million in 2023 to RMB 143.8 million in 2024, a reduction of 45.8 million [1] - The gross profit increased by 30.5% from RMB 46.8 million for the year ending December 31, 2023, to RMB 61.1 million for the year ending December 31, 2024, with a gross margin of 85.0% compared to 70.3% in the previous year [1] Group 2 - The company has one commercialized product and 19 items in its research pipeline, with its core product, Uterilone Injection, approved for market in 2021 for treating recurrent or metastatic breast cancer [2] - Uterilone Injection is the only chemotherapy drug developed using synthetic biology technology that has been approved in China, marking a significant milestone in the availability of domestically developed innovative chemotherapy drugs [2] - The company plans to enhance its research and development investments to improve the commercial value of its product pipeline through both in-house development and external collaborations [2]
华昊中天医药-B(02563.HK)公布年度业绩 毛利率大幅提高 将进一步加强研发投入